Apama Medical announces claim coverage in China for electrode-based ablation balloon for the treatment of atrial fibrillation

464

Apama Medical announced receipt of a Chinese notice of allowance for claims covering their low profile electrode assembly that enables the attachment of flexible electrodes to an ablation balloon for energy delivery and monitoring.

According to a press release, the Chinese patent will complement an existing US patent giving Apama broad claim coverage for electrode-based ablation balloons in the US and China for the treatment of atrial fibrillation. Utilising this patented electrode technology enables Apama to design the only ablation catheter that performs a full pulmonary vein ablation and rotor ablation in a single-shot.

“Accurate energy delivery and monitoring are a challenge during ablation procedures since success often depends on a multitude of discrete catheter manipulations,” stated Amr Salahieh, Apama president and chief executive officer. “Our proprietary design offers multipoint, customisable single-shot ablation and eliminates the need for excessive catheter rotations and serial point ablations. This simplifies the current procedure and reduces time, which allows for more patients to be treated.”